Details

Last Funding Type

Private Equity（PE）

Last Funding Money Raised

$65M

Industries

Biotechnology,Genetics,Health Care,Health Diagnostics,Life Science,Medical

Founded date

Jan 1, 2003

Number Of Employee

101 - 250

Operating Status

Active

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.